Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics

Size: px
Start display at page:

Download "Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics"

Transcription

1 Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics Richard Sheppard MD FRCPC Director of Heart Failure Research Heart Function Clinic Jewish General hospital

2 Objectives 1. Discuss the epidemiology of chemotherapyinduced cardiotoxicity (focus on changes in left ventricular function) in the context of the some specific agents. 2. Discuss the current approach to treatment of established cardiomyopathy from chemotherapeutic agents in the treatment.

3 Role of the Clinical Cardiologist Interaction of the oncologist with: General Cardiologist Often first line Heart Failure Specialist Severe LV Dysfunction Echocardiographer Questions related to reports or imaging quality/interpretation

4 Chemotherapy and cardiotoxicity Roles of the Cardiologist Clinical assessment Identifying risk factors Symptomatic Asymptomatic Can my patient get chemotherapy? Organizing Follow-up Medical therapy Echocardiography 2D 3D MUGA DEFINING CARDIOTOXICITY

5 Chemotherapy and cardiotoxicity: Anthracyclines Trastuzumab Kinase Inhibitors The Agents Others Other chemotherapeutic agents Radiation

6 Cumulative probability of developing doxorubicin-induced congestive heart failure (CHF) plotted against total cumulative dose of doxorubicin in all patients receiving the drug (3941 patients; 88 cases of congestive heart failure). Anthracyclines Shan K et al. Ann Intern Med 1996;125:47-58

7 Anthracyclines Oxidative stress with myocardial fibrosis and necrosis Possible direct toxic effect on local adrenergic neurotransmission that impacts myocardial contraction Apoptosis and dysregulation of calcium homeostasis in sarcoplasmic reticulum

8 Epidemiology AC Toxicity Anthracyclines Some studies suggest 60% 2-year mortality (older data, less SOC therapy) Over 50% of all patients exposed show some cardiac dysfunction up to 20 years later and 5% will have overt HF symptoms Acute, early and late toxicity Dose dependent

9 Epidemiology AC Toxicity Smith et al BMC Cancer AC Increases risk of cardiotoxicity by 5.43 fold Increases risk of sub-clinical cardiotoxicity by 6.25 fold Any cardiotoxicity is increased by 2.27 fold Risk of cardiac death increases by 4.94 fold Higher risk with bolus compared to infusions Lower risk with epirubicin and liposomal doxorubicin and with cardioprotective agents (dexrazoxane)

10 AC Toxicity

11 Trastuzumab HER2-receptor blockade HER2 Receptors are there for embryonic cardiac development Protection against cardiotoxins HER2 levels elevated in HF and LV Dysfunction (inverse correlation) Knockout Mice with no gene show signs of Dilated CMP and susceptibility to anthracycline induced cardiotoxicity

12 Trastuzumab (Herceptin) First signs were in Slamon et al. NEJM 2001 Phase III, 469 patients AC+ HER (also a group with paclitaxel) vs. AC alone in metastatic breast cancer 28% symptomatic/asymptomatic cardiotoxicity in patients receiving herceptin vs. 8% who did not. Among the patients with toxicity, most with NYHA III-IV were in the AC group with herceptin After CREC formed (Cardiac Review and Evaluation Committee) examined reviewed Range of 3-7% using single agent rx Incidence of severe HF and cardiac death ranges from 0.6% to 4%

13 Trastuzumab (Herceptin)

14 Kinase Inhibitors

15 Kinase Inhibitors Nat Rev Drug Disc 2011

16 Kinase Inhibitors Unintended inhibition of specific kinases Kinases in the cardiomyocyte that are essential for cell survival In study of GI stromal tumors, 18% of patients getting Sutent had CHF or > 15 point decline in EF (Chu et al. Lancet 2007) One other safety study of Tykerb (lapatinib) suggesting cardiotoxicity

17 Kinase Inhibitors No good predictors, to date Ongoing studies Human studies focus on imaging and biomarkers Animal studies focus on models of cardiotoxicity, as in zebra fish and rodent models to better understand CV development There are also potential CV benefits of these meds: Pulmonary HTN Autoimmune diabetes Restenosis post PCI Post MI remodeling Genetic forms of HCM

18 Therapies in Chemotherapy Associated Cardiotoxicity Defining cardiotoxicity remains a challenge Who do you treat? What therapy do you use? What is end point for therapy? Can you ever stop therapy?

19 Therapies in Chemotherapy Associated Cardiotoxicity Cardinale et al. Circ Treatment with ACEi based on troponin I elevation after HDC Started 1 month after last cycle HDC for 1 year Normal EF at baseline Primary Endpoint : Drop of > 10 units, less than 50%

20 Therapies in Chemotherapy Associated Cardiotoxicity Nakamae et al. Cancer patients CHOP with or without 80 mg Valsartan

21

22 Therapies in Chemotherapy Associated Cardiotoxicity Kalay et al. JACC patients getting anthracycline (ANT) Coreg 12.5 mg po qd started before ANT and up to 6 months after End Point was LVEF

23 Therapies in Chemotherapy Associated Cardiotoxicity Acar et al. JACC patients undergoing ANT therapy 40 mg of atorvastatin vs. no statin (anti-oxidative, anti-inflammatory) 1 cycle per month End point was LVEF

24 From Bench to Bedside Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, Gosavi S, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M Am J Cardiol 2011;107:

25 Univariate analysis of predictors of cardiotoxicity The change of LVEF at 3 months was not predictive of later cardiotoxicity The change in L-S, R-S and troponins at 3 months was predictive of later cardiotoxicity

26 Results By multiple regression analysis, (1) a longitudinal strain; and, (2) hs-tn-i were independent predictors of later cardiotoxicity Whereas patients with both findings have a 9-fold increase in the risk of CIC, The absence of either confers significant protection where only 3% develop CIC

27 Summary Established therapies and novel therapies Definition of cardiotoxicity Management aimed specifically at cardiotoxicity Imaging of patients with (potential) cardiotoxicity Predicting Cardiotoxicity

28 Future Directions Cardiology-Oncology Link Clinical Care Cardiology consultation when, where? Follow-up Cardio-Oncology Program initiative

Cardiotoxicity: The View of the Cardiologist

Cardiotoxicity: The View of the Cardiologist Cardiotoxicity: The View of the Cardiologist Dr. Yael Peled, Cardio-Oncology Interactions: 1.Cardiotoxicity following chemotherapy 2. Co existence of cancer and CVD Aging & common risk factors cardiac

More information

Cancer survivors. Half of Cancer Survivors Die of Other Conditions. Cause of Death in Cancer Survivors

Cancer survivors. Half of Cancer Survivors Die of Other Conditions. Cause of Death in Cancer Survivors Cardiotoxicity of Cancer Therapies: Pathogenesis, Diagnosis, and Management Edward T.H. Yeh, M.D. Cancer survivors Now nearly 12 million cancer survivors in U.S. according to NCI 15% were diagnosed 2+

More information

Chemotherapy- Associated Heart Failure. M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY

Chemotherapy- Associated Heart Failure. M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY Chemotherapy- Associated Heart Failure M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY In last 20 years life-expectancy for patients with cancer

More information

CV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long

CV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long CV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Albert

More information

Cardio-Oncology: Advancing Cardiovascular Care of the Oncology Patient

Cardio-Oncology: Advancing Cardiovascular Care of the Oncology Patient Cardio-Oncology: Advancing Cardiovascular Care of the Oncology Patient Vijay U. Rao, MD, PhD, FACC, FASE Franciscan Physician Network Indiana Heart Physicians Director, Franciscan Health Inpatient Heart

More information

Guideline-Driven Care in Cardio- Oncology: Utilizing Recommendations Across Disciplines

Guideline-Driven Care in Cardio- Oncology: Utilizing Recommendations Across Disciplines Guideline-Driven Care in Cardio- Oncology: Utilizing Recommendations Across Disciplines Jennifer Liu, MD FACC FASE Director of CV Laboratories Associate Professor of Clinical Medicine Memorial Sloan Kettering

More information

Advanced Echocardiography in the Evaluation of Chemotherapy Patients

Advanced Echocardiography in the Evaluation of Chemotherapy Patients Advanced Echocardiography in the Evaluation of Chemotherapy Patients Juan Carlos Plana, MD, FACC, FASE Co-Director, Cardio-Oncology Center Section of Cardiovascular Imaging Department of Cardiovascular

More information

Cardio-oncology: Basics and Knowing When You Need an Echo

Cardio-oncology: Basics and Knowing When You Need an Echo Cardio-oncology: Basics and Knowing When You Need an Echo Vera H. Rigolin, MD, FASE, FACC, FAHA Professor of Medicine Northwestern University Feinberg School of Medicine Medical Director, Echocardiography

More information

Building a Cardio-Oncology Program

Building a Cardio-Oncology Program Building a Cardio-Oncology Program Marielle Scherrer-Crosbie, MD, PhD Professor of Medicine Director of Echocardiography University of Pennsylvania Philadelphia, PA Co-Director, Cardio-Oncology Program

More information

Can point of care cardiac biomarker testing guide cardiac safety during oncology trials?

Can point of care cardiac biomarker testing guide cardiac safety during oncology trials? Can point of care cardiac biomarker testing guide cardiac safety during oncology trials? Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Clinical Research Vanderbilt University

More information

CardioOncology: The Promise and Pitfalls of Personalized Medicine

CardioOncology: The Promise and Pitfalls of Personalized Medicine CardioOncology: The Promise and Pitfalls of Personalized Medicine Vijay U. Rao, MD, PhD, FACC, FASE, FHFSA Franciscan Physician Network Indiana Heart Physicians Director, Franciscan Health Inpatient Heart

More information

Ian Paterson, Mazankowski Alberta Heart Institute Division of Cardiology, University of Alberta

Ian Paterson, Mazankowski Alberta Heart Institute Division of Cardiology, University of Alberta Ian Paterson, Mazankowski Alberta Heart Institute Division of Cardiology, University of Alberta Peer Reviewed Funding: CIHR, ACF, AI-HS Industry: Servier Canada Inc, RocheCanada Inc. What is your approach

More information

Anthracycline cardiomypathy in breast cancer: detection and prevention in high-risk patients

Anthracycline cardiomypathy in breast cancer: detection and prevention in high-risk patients Anthracycline cardiomypathy in breast cancer: detection and prevention in high-risk patients Scottish Cancer Trials Breast Group Meeting Thursday 2 nd February 2017 Dr Peter Henriksen Edinburgh Heart Centre

More information

Cardio-oncology: Applying new echo technology to guide therapy

Cardio-oncology: Applying new echo technology to guide therapy Cardio-oncology: Applying new echo technology to guide therapy Dinesh Thavendiranathan MD, SM, FRCPC, FASE Director, Ted Rogers Program in Cardiotoxicity Prevention Assistant Professor of Medicine Division

More information

Potpourri: Cardio-Oncology Cases

Potpourri: Cardio-Oncology Cases Potpourri: Cardio-Oncology Cases Judy Hung, MD Massachusetts General Hospital Harvard Medical School No disclosures; Thank Michael Picard and Tomas Neilan for cases 59 year old woman (sister diagnosed

More information

03/14/2019. Scope of the Problem. Objectives

03/14/2019. Scope of the Problem. Objectives Cardiac Consideration During and After Breast Cancer Treatment Indu G. Poornima M.D Division of Cardiology Scope of the Problem 1 in 8 women will develop breast cancer 3.3 million women are survivors CVD

More information

How to Evaluate the Heart of Elderly Patients

How to Evaluate the Heart of Elderly Patients How to Evaluate the Heart of Elderly Patients Special considerations regarding cardiotoxicity Michael S. Ewer MD The University of Texas M. D. Anderson Cancer Center Why Discuss Cardiac Disease and Cancer

More information

Cardiotoxicity Effects of Chemotherapeutic Drugs

Cardiotoxicity Effects of Chemotherapeutic Drugs Cardiotoxicity Effects of Chemotherapeutic Drugs Allan L Klein M.D. Director, Center of Pericardial Diseases Professor of Medicine Heart and Vascular Institute Cleveland Clinic President, ASE * No conflicts

More information

Managing LV Impairment with Cancer Therapies

Managing LV Impairment with Cancer Therapies British Society for Heart Failure Revalidation & Training Day London, March 2017 Managing LV Impairment with Cancer Therapies Zaheer Yousef BSc MBBS MD FESC FRCP Heart Muscle Diseases & Heart Function

More information

Multiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity

Multiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity Multiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity Cory V. Noel, M.D. Medical Director of CMR Pediatric Cardiology Outline What is meant by the term cardiotoxicity? Scope of

More information

Vasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension Arrhythmias Miscellaneous ( pericardial inflammation, valvular abnormalities )

Vasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension Arrhythmias Miscellaneous ( pericardial inflammation, valvular abnormalities ) Management of Cardiotoxicity due to Systemic Cancer Therapy Left Ventricular Dysfunction Type 1 cardiac dysfunction Type 2 cardiac dysfunction Vasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension

More information

Cured of Cancer but now Let s Heal the Heart An exploration into the effects of cancer on the heart

Cured of Cancer but now Let s Heal the Heart An exploration into the effects of cancer on the heart Cured of Cancer but now Let s Heal the Heart An exploration into the effects of cancer on the heart Suma H. Konety, MD, MS Associate Professor, Cardiovascular Division University of Minnesota What is Cardio-Oncology?

More information

New Cardiac Guidelines Where They Agree, Where They Differ, and How Does It Affect Patient Care

New Cardiac Guidelines Where They Agree, Where They Differ, and How Does It Affect Patient Care New Cardiac Guidelines Where They Agree, Where They Differ, and How Does It Affect Patient Care Sandra M Swain, MD, FACP, FASCO Professor of Medicine Associate Dean for Research Development Georgetown

More information

Cardio-Oncology at MHI. Kasia Hryniewicz, M.D.

Cardio-Oncology at MHI. Kasia Hryniewicz, M.D. Minneapolis Heart Institute at Abbott Northwestern Hospital Cardio-Oncology at MHI Cardiovascular Nursing Conference Kasia Hryniewicz, M.D. October 7 th, 2015 No disclosure 1 Why cardio-oncology? Background

More information

Cardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer

Cardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer Cardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer Dr. Chris Fryer, Pediatric Oncologist, BC Children s Hospital Dr. Sean Virani, Founding Director, UBC Cardiovascular Oncology

More information

Breast Cancer and the Heart

Breast Cancer and the Heart Breast Cancer and the Heart Anne H. Blaes, M.D., M.S. Associate Professor University of Minnesota Hematology/Oncology Director, Adult Cancer Survivor Clinic No disclosures Objectives Discuss cardiac complications

More information

Disclosures. Objectives. SK continued. Two of my patients. First and foremost, why is this important??? 10/26/2016

Disclosures. Objectives. SK continued. Two of my patients. First and foremost, why is this important??? 10/26/2016 Disclosures Bayer Pharmaceuticals: clinical trial investigator KellyAnn Light-McGroary, MD, FACC Clinical Assistant Professor Cardiomyopathy Treatment Program University of Iowa Hospitals and Clinics Chief

More information

Cancer and the heart: New evidence and open issues

Cancer and the heart: New evidence and open issues Cancer and the heart: New evidence and open issues Dimitrios Farmakis, MD, PhD, FESC Assist. Professor, European University Cyprus Cardio-Oncology Clinic, Heart Failure Unit, Attikon Hospital Cardiac Clinic

More information

Practice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy

Practice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy Practice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy JEAN-BERNARD DURAND, M.D., FCCP, FACC,FACP,FHFSA,FAHA PROFESSOR OF MEDICINE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

More information

Cardiac Toxicities Associated with Cancer Treatment

Cardiac Toxicities Associated with Cancer Treatment Cardiac Toxicities Associated with Cancer Treatment Hot Topics in Oncology Care 2017 Silicon Valley Oncology Nursing Society Christine Miaskowski, RN, PhD, FAAN American Cancer Society Clinical Research

More information

12/16/16. Cardio-oncology: A practical overview for the cardiologist. Disclosures. Learner Objectives. Case 1

12/16/16. Cardio-oncology: A practical overview for the cardiologist. Disclosures. Learner Objectives. Case 1 Disclosures I have no relevant financial disclosures. Division of Cardiology Department of Medicine Rajni Rao, MD Associate Professor of Medicine Cardio-oncology: A practical overview for the cardiologist

More information

Roohi Ismail-Khan, MD, MS

Roohi Ismail-Khan, MD, MS Roohi Ismail-Khan, MD, MS Associate Member Department of Breast Oncology H. Lee Moffitt Cancer Center Associate Professor University of South Florida Department of Oncological Sciences September 27, 2018

More information

Μυοκαρδιοπάθεια από τη θεραπεία του καρκίνου. Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα

Μυοκαρδιοπάθεια από τη θεραπεία του καρκίνου. Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα Μυοκαρδιοπάθεια από τη θεραπεία του καρκίνου Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα Estimated and projected cancer survivors in USA de Moor JS et al. Cancer Epidemiol Biomarkers Prev 2013 Causes of

More information

Survivorship: Managing Cardiac Toxicities

Survivorship: Managing Cardiac Toxicities Survivorship: Managing Cardiac Toxicities Anecita Fadol, PhD, RN, FNP-BC, FAANP The University of Texas MD Anderson Cancer Center Learning Objectives Identify the causes of cardiac toxicity in cancer survivors

More information

Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO Clinical Practice Guideline

Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO Clinical Practice Guideline Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO Clinical Practice Guideline J Clin Oncol. 2016 Dec 5:JCO2016705400. [Epub ahead of print] Objectives: Improve the quality

More information

Do we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD

Do we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD Do we have to change our anti-cancer strategy in case of cardiac toxicity? Point of view of the oncologist Guy Jerusalem, MD, PhD CHU Sart Tilman Liège Anticancer therapy: cardiac toxicity New anticancer

More information

Summary of risk management plan for Trazimera (trastuzumab)

Summary of risk management plan for Trazimera (trastuzumab) Summary of risk management plan for Trazimera (trastuzumab) Summary of risk management plan for PF-05280014 (trastuzumab) 1 This is a summary of the RMP for PF-05280014. The RMP details important risks

More information

Cardio oncology Double Jeopardy

Cardio oncology Double Jeopardy Cardio oncology Double Jeopardy Edie Pituskin RN MN (NP Adult) PhD NP Forum for Nursing and Allied Health, April 10, 2015 Aims Describe the double jeopardy faced by cancer patients Discuss issues in detection

More information

Case Study in Cancer and Cardiotoxicity

Case Study in Cancer and Cardiotoxicity Case Study in Cancer and Cardiotoxicity JEAN-BERNARD DURAND, M.D., FCCP, FACC ASSOCIATE PROFESSOR OF MEDICINE MEDICAL DIRECTOR CARDIOMYOPATHY SERVICES UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER HOUSTON,

More information

Cardiovascular outcomes in survivors of childhood cancer

Cardiovascular outcomes in survivors of childhood cancer Cardiovascular outcomes in survivors of childhood cancer Paul Nathan MD, MSc Director, AfterCare Program Division of Haematology/Oncology The Hospital for Sick Children, Toronto Conflicts Nothing to declare

More information

Γυναίκα 67 ετών 2 η μετεγχειρητική ημέρα μετά αφαίρεση μονήρους πνευμονικού όγκου στον άνω λοβό του αριστερού πνεύμονα Οξύ πρόσθιο STEMI

Γυναίκα 67 ετών 2 η μετεγχειρητική ημέρα μετά αφαίρεση μονήρους πνευμονικού όγκου στον άνω λοβό του αριστερού πνεύμονα Οξύ πρόσθιο STEMI Γυναίκα 67 ετών 2 η μετεγχειρητική ημέρα μετά αφαίρεση μονήρους πνευμονικού όγκου στον άνω λοβό του αριστερού πνεύμονα Οξύ πρόσθιο STEMI Οικογενειακό ιστορικό νεοπλασιών: αρνητικό Σύντομο ατομικό ιστορικό:

More information

RECONCILING GUIDELINES, RECOMMENDATIONS AND CONSENSUS STATEMENTS TO PROVIDE OPTIMAL CARDIO-ONCOLOGY CARE

RECONCILING GUIDELINES, RECOMMENDATIONS AND CONSENSUS STATEMENTS TO PROVIDE OPTIMAL CARDIO-ONCOLOGY CARE RECONCILING GUIDELINES, RECOMMENDATIONS AND CONSENSUS STATEMENTS TO PROVIDE OPTIMAL CARDIO-ONCOLOGY CARE SARO ARMENIAN, DO, MPH ASSOCIATE PROFESSOR, DEPARTMENTS OF PEDIATRICS AND POPULATION SCIENCES DIRECTOR,

More information

Conflict of interest: none declared

Conflict of interest: none declared The value of left ventricular global longitudinal strain assessed by three-dimensional strain imaging in the early detection of anthracycline-mediated cardiotoxicity C. Mornoş, A. Ionac, D. Cozma, S. Pescariu,

More information

Trastuzumab (IV) Monotherapy - 7 days

Trastuzumab (IV) Monotherapy - 7 days INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 7 days Regimen *Reimbursement INDICATION ICD10 Code Status Treatment of patients with HER2 positive metastatic breast cancer (MBC) C50 00201a Hospital

More information

SIOG APAC th to 13 th July

SIOG APAC th to 13 th July SIOG APAC 2014 12 th to 13 th July Breast Cancer in Older Adults Cardiac Toxicity in Breast Cancer Dr Vivianne Shih, Pharm.D., BCPS, BCOP Specialist Pharmacist (Oncology) 1 Learning Objectives At the end

More information

A Step Forward in Cancer Patient Care:

A Step Forward in Cancer Patient Care: Hong Kong Pharmacy Conference 2018 A Step Forward in Cancer Patient Care: The Experience of Oncology Pharmacist-Managed Trastuzumab Clinic in Queen Mary Hospital Amy Yuen Clinical Pharmacist 24 Oct 2017.

More information

Matters of the heart: cardiac toxicity of adjuvant systemic therapy for earlystage breast cancer

Matters of the heart: cardiac toxicity of adjuvant systemic therapy for earlystage breast cancer CARDIAC TOXICITY MEDICAL ONCOLOGY Matters of the heart: cardiac toxicity of adjuvant systemic therapy for earlystage breast cancer K. Towns MD,* P.L. Bedard MD, and S. Verma MD MSEd ABSTRACT Breast cancer

More information

Does understanding the biology of cardiac injury from cancer therapy lead to new cardiac therapy? Carrie Geisberg MD, MSCI Vanderbilt University

Does understanding the biology of cardiac injury from cancer therapy lead to new cardiac therapy? Carrie Geisberg MD, MSCI Vanderbilt University Does understanding the biology of cardiac injury from cancer therapy lead to new cardiac therapy? Carrie Geisberg MD, MSCI Vanderbilt University No financial disclosures Disclosures Funded by: VCTRS career

More information

Cardiovascular Imaging Endpoints in Oncology Clinical Trials

Cardiovascular Imaging Endpoints in Oncology Clinical Trials Cardiovascular Imaging Endpoints in Oncology Clinical Trials Bonnie Ky, MD, MSCE Assistant Professor of Medicine and Epidemiology Director, Penn Cardio-Oncology Center of Excellence Director, Penn Center

More information

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the

More information

Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA

Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine

More information

NCCP Chemotherapy Regimen

NCCP Chemotherapy Regimen INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 21 days Regimen *Reimbursement INDICATION ICD10 Code Status HER2 positive metastatic breast cancer (MBC) C50 00200a Hospital HER2 positive early breast

More information

CARDIOTOXICITY IN ONCOLOGY PRACTICE

CARDIOTOXICITY IN ONCOLOGY PRACTICE CARDIOTOXICITY IN ONCOLOGY PRACTICE Evandro de Azambuja, MD, PhD Jules Bordet Institute, Brussels, Belgium CARDIOTOXICITY: THE MAGNITUDE OF THE PROBLEM Advances in cancer treatments have improved patients

More information

The Road to Improve Cardiovascular Health after Cancer. S. Carolina Masri, MD Cardiology Division University of Washington, Seattle June 2 nd 2018

The Road to Improve Cardiovascular Health after Cancer. S. Carolina Masri, MD Cardiology Division University of Washington, Seattle June 2 nd 2018 The Road to Improve Cardiovascular Health after Cancer S. Carolina Masri, MD Cardiology Division University of Washington, Seattle June 2 nd 2018 Objective What are the cardiac complications in cancer

More information

CASE STUDIES CLINICAL CASE SCENARIOS. Matthew J. Ellis, MD, PhD

CASE STUDIES CLINICAL CASE SCENARIOS. Matthew J. Ellis, MD, PhD CLINICAL CASE SCENARIOS Matthew J. Ellis, MD, PhD Clinicians face daily challenges in the management of individual patients with breast cancer who demonstrate different characteristics in terms of estrogen

More information

Update in Cardio-Oncology

Update in Cardio-Oncology Update in Cardio-Oncology Dr. Alexander Lyon BHF Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK President of British Cardio-Oncology Society

More information

Redefining Cardiac Eligibility Thresholds in Oncology Trials. Role of Cardiovascular Core Labs

Redefining Cardiac Eligibility Thresholds in Oncology Trials. Role of Cardiovascular Core Labs Redefining Cardiac Eligibility Thresholds in Oncology Trials. Role of Cardiovascular Core Labs Ana Barac, MD, PhD, FACC Associate Professor of Medicine, Georgetown University MedStar Heart and Vascular

More information

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast

More information

Strain and Strain Rate Imaging How, Why and When?

Strain and Strain Rate Imaging How, Why and When? Strain and Strain Rate Imaging How, Why and When? João L. Cavalcante, MD Advanced Cardiac Imaging Fellow Cleveland Clinic Foundation Disclosures: No conflicts of interest Movement vs Deformation Movement

More information

Journal of Breast Cancer

Journal of Breast Cancer Journal of Breast Cancer ORIGINAL ARTICLE J Breast Cancer 2013 June; 16(2): 178-183 Early Cardiac Function Monitoring for Detection of Subclinical Doxorubicin Cardiotoxicity in Young Adult Patients with

More information

Clinical Perspective: How Are We Doing From a Clinician s Point of View

Clinical Perspective: How Are We Doing From a Clinician s Point of View Clinical Perspective: How Are We Doing From a Clinician s Point of View Steven E. Lipshultz, MD Department of Pediatrics University of Miami Miller School of Medicine Holtz Children s Hospital of the University

More information

Diastolic Heart Failure

Diastolic Heart Failure Diastolic Heart Failure Presented by: Robert Roberts, M.D., FRCPC, MACC, FAHA, FRSC Professor of Medicine and Chair ISCTR University of Arizona, College of Medicine Phoenix Scientist Emeritus and Advisor,

More information

Therapeutic Targets and Interventions

Therapeutic Targets and Interventions Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium

More information

CKD Satellite Symposium

CKD Satellite Symposium CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%

More information

Heart Failure Management Update

Heart Failure Management Update Heart Failure Management Update Rafique Ahmed, MD, PhD, FACC, FCPS Consultant Cardiac Electrophysiologist Baltimore, Maryland, USA Heart Failure - Definition The situation when the heart is incapable of

More information

Cardio-Oncology: Cardiac care specific to cancer patients and survivors. Learning Objectives

Cardio-Oncology: Cardiac care specific to cancer patients and survivors. Learning Objectives Cardio-Oncology: Cardiac care specific to cancer patients and survivors Lavanya Kondapalli MD, FACC Assistant Professor of Medicine, Division of Cardiology Director of Cardio-Oncology Learning Objectives

More information

Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx

Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx 5 th Annual Echo Florida, October 2016 Vincent L. Sorrell, MD Anthony N. DeMaria Professor of Medicine (Card/ Rad) University

More information

Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1

Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1 Important data from BCIRG 006 Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1 in the adjuvant treatment of HER2+ breast

More information

Non-Anthracycline Adjuvant Therapy: When to Use?

Non-Anthracycline Adjuvant Therapy: When to Use? Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for

More information

When is strain assessment mandatory?

When is strain assessment mandatory? When is strain assessment mandatory? Geneviève Derumeaux University of Lyon France Presenter Disclosure Information Geneviève Derumeaux When is strain assessment mandatory? DISCLOSURE INFORMATION: None

More information

Anthracyclines in the elderly breast cancer patients

Anthracyclines in the elderly breast cancer patients Anthracyclines in the elderly breast cancer patients Etienne GC Brain, MD PhD Medical Oncology Centre René Huguenin, Saint-Cloud & Group GERICO, FNCLCC, Paris Centre René Huguenin - Saint-Cloud Facts about

More information

Cardiotoxicities of Cancer in Childhood Cancer Survivors

Cardiotoxicities of Cancer in Childhood Cancer Survivors Cardiotoxicities of Cancer in Childhood Cancer Survivors Steven E. Lipshultz, MD Department of Pediatrics Wayne State University School of Medicine Children s Hospital of Michigan Detroit, MI, USA Stages

More information

Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx. No Real or Potential Conflict of Interests for this Talk CTRCD

Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx. No Real or Potential Conflict of Interests for this Talk CTRCD Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx Vincent L. Sorrell, MD Anthony N. DeMaria Professor of Medicine University of Kentucky / Gill Heart & Vascular Institute

More information

Φαρμακευτική θεραπεία της μετεμφραγματικής καρδιακής ανεπάρκειας. Α. Καραβίδας Υπεύθυνος ιατρείου καρδιακής ανεπάρκειας Γ.Ν.Α Γ.

Φαρμακευτική θεραπεία της μετεμφραγματικής καρδιακής ανεπάρκειας. Α. Καραβίδας Υπεύθυνος ιατρείου καρδιακής ανεπάρκειας Γ.Ν.Α Γ. Φαρμακευτική θεραπεία της μετεμφραγματικής καρδιακής ανεπάρκειας Α. Καραβίδας Υπεύθυνος ιατρείου καρδιακής ανεπάρκειας Γ.Ν.Α Γ.Γεννηματάς Clinical Trials on Fibrinolysis N = 61.41 AMI pts, ( GUSTO I, GUSTOIIb,

More information

4/5/2017. Chemotherapy Related Cardiac Dysfunction & How a Cardiology Oncology Clinic Can Help! Cancer. Cancer Treatment Patient.

4/5/2017. Chemotherapy Related Cardiac Dysfunction & How a Cardiology Oncology Clinic Can Help! Cancer. Cancer Treatment Patient. hemotherapy Related ys & How a ardiology ncology linic an Help! April 22, 2017 Maria Anwar, BScharm, AR maria.anwar@ahs.ca Key Learning bjectives To provide a brief background about cardio oncology To

More information

CARDIAC ISSUES IN CANCER SURVIVORS Jean-Bernard Durand, M.D.

CARDIAC ISSUES IN CANCER SURVIVORS Jean-Bernard Durand, M.D. CARDIAC ISSUES IN CANCER SURVIVORS Jean-Bernard Durand, M.D. Hello, my name is John-Bernard Durand. I m an Associate Professor of Medicine at University of Texas MD Anderson Cancer Center, and I ve been

More information

Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece

Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants

More information

Late Effects of Treatment on the Heart. Jennifer H. Jordan, PhD, MS William O. Ntim, MD, FACC, FACP

Late Effects of Treatment on the Heart. Jennifer H. Jordan, PhD, MS William O. Ntim, MD, FACC, FACP Late Effects of Treatment on the Heart Jennifer H. Jordan, PhD, MS William O. Ntim, MD, FACC, FACP Panel Speakers Jennifer H. Jordan, PhD, MS Assistant Professor, Cardiovascular Medicine Comprehensive

More information

The breast cancer patient in the cardioncology unit

The breast cancer patient in the cardioncology unit Review Article The breast cancer patient in the cardioncology unit Daniela Cardinale, Vincenzo Caruso, Carlo M. Cipolla Cardioncology Unit, Cardiology Division, IEO, European Istitute of Oncology, IRCCS,

More information

RADIATION HEART DISEASE: MANAGEMENT STRATEGIES

RADIATION HEART DISEASE: MANAGEMENT STRATEGIES RADIATION HEART DISEASE: MANAGEMENT STRATEGIES AMMAR CHAUDHARY MBChB, ABIM, FRCPC ASSOCIATE CONSULTANT CARDIOLOGIST KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTER - JEDDAH Scope of the Problem ~ 50

More information

Cycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline

Cycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline BC Cancer Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab (HERCEPTIN), and PACLItaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code:

More information

BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN)

BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN) BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code: Tumour Group: Contact Physician: UBRAJTTW Breast Dr. Angela Chan ELIGIBILITY:

More information

Ο ογκολογικός ασθενής και η καρδιά του

Ο ογκολογικός ασθενής και η καρδιά του Ο ογκολογικός ασθενής και η καρδιά του Δημήτρης Φαρμάκης Αν. Καθηγητής, Πανεπιστήμιο Κύπρου Καρδιακή Ανεπάρκεια & Καρδιο-Ογκολογία, ΠΓΝ «Αττικόν» Disclosures Consultation fees, speaker honoraria or travel

More information

Cardio-Oncology Toxicities and Management

Cardio-Oncology Toxicities and Management Cardio-Oncology Toxicities and Management Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies April 21, 2017 Michel G. Khouri, MD Assistant Professor of Medicine Division

More information

Click to edit Master title style

Click to edit Master title style Click to edit Master title style Cardio-Oncology: A Historical Perspective Past, Present and Future Susan Dent, MD, FRCPC Medical Oncologist, Duke Cancer Institute Professor of Medicine Associate Director,

More information

The Role of ICD Therapy in Cardiac Resynchronization

The Role of ICD Therapy in Cardiac Resynchronization The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine

More information

Heart Failure: Combination Treatment Strategies

Heart Failure: Combination Treatment Strategies Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia

More information

Importance of CRT team for optimization of the results: a European point of view

Importance of CRT team for optimization of the results: a European point of view Importance of CRT team for optimization of the results: a European point of view Matteo Bertini, MD, PhD Arcispedale S. Anna Azienda Ospedaliero-Universitaria Cona-Ferrara No conflict of interest to declare

More information

Susan P. D Anna MSN, APRN BC February 14, 2019

Susan P. D Anna MSN, APRN BC February 14, 2019 Is there Equal Opportunity in Heart Failure?? Susan P. D Anna MSN, APRN BC February 14, 2019 Disclosures: I have no financial disclosures. I am not an expert on this topic, but see a lot of women with

More information

The Heart of the Matter: Issues in Cardio-Oncology Research

The Heart of the Matter: Issues in Cardio-Oncology Research The Heart of the Matter: Issues in Cardio-Oncology Research Edith Pituskin RN MN Nurse Practitioner, Radiation Oncology, Cross Cancer Institute PhD (c), Faculty of Rehabilitation Medicine, University of

More information

Restrictive Cardiomyopathy

Restrictive Cardiomyopathy ESC Congress 2011, Paris Imaging Unusual Causes of Cardiomyopathy Restrictive Cardiomyopathy Kazuaki Tanabe, MD, PhD Professor of Medicine Chair, Division of Cardiology Izumo, Japan I Have No Disclosures

More information

Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure

Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues

More information

Cardio-Oncology: Past Present and Future

Cardio-Oncology: Past Present and Future Cardio-Oncology: Past Present and Future Lakkana Suwannoi PharmD BCPS BCOP Division of Clinical Pharmacy Faculty of Pharmacy Mahidol University Bangkok THAILAND Outline I. Cardiovascular disease & cancer

More information

1/27/2018 THE WAY FORWARD: AN EMERGING FIELD OF CARDIO-ONCOLOGY LEARNING OBJECTIVES. Cardiology and Oncology. Why to Discuss Together..

1/27/2018 THE WAY FORWARD: AN EMERGING FIELD OF CARDIO-ONCOLOGY LEARNING OBJECTIVES. Cardiology and Oncology. Why to Discuss Together.. LEARNING OBJECTIVES THE WAY FORWARD: AN EMERGING FIELD OF CARDIO-ONCOLOGY MARIANNA KRIVE, DO ADVOCATE HEART INSTITUTE AMG-PARKSIDE CARDIOLOGY 1.Explain the foundation and the medical need for cardio-oncology

More information

VECTORS OF CONTRACTION

VECTORS OF CONTRACTION 1/3/216 Strain, Strain Rate, and Torsion: Myocardial Mechanics Simplified and Applied VECTORS OF CONTRACTION John Gorcsan, MD University of Pittsburgh, Pittsburgh, PA Shortening Thickening Twisting No

More information

Heart Failure: The Frequent, Forgotten and often Fatal Complication of Type 2 Diabetes

Heart Failure: The Frequent, Forgotten and often Fatal Complication of Type 2 Diabetes Heart Failure: The Frequent, Forgotten and often Fatal Complication of Type 2 Diabetes DAVID S. H. BELL CHAIRMAN BELL, DSH. DIABETES CARE(2003)26:2433-41. Speaker s Bureau: AstraZeneca Novo Nordisk Janssen

More information

CARDIOVASCULAR TOXICITY INDUCED BY ANTITUMOUR THERAPY. Florian SCOTTE, MDPhD Suresnes, France

CARDIOVASCULAR TOXICITY INDUCED BY ANTITUMOUR THERAPY. Florian SCOTTE, MDPhD Suresnes, France CARDIOVASCULAR TOXICITY INDUCED BY ANTITUMOUR THERAPY Florian SCOTTE, MDPhD Suresnes, France DISCLOSURES Consultant / Advisory Boards / Speaker: Tesaro, Sanofi, Roche, MSD, TEVA, Norgine, Prostrakan, Leo

More information

Antialdosterone treatment in heart failure

Antialdosterone treatment in heart failure Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition

More information

Heart Failure. GP Update Refresher 18 th January 2018

Heart Failure. GP Update Refresher 18 th January 2018 GP Update Refresher 18 th January 2018 Heart Failure Dr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK President of British

More information

ASNC INFORMATION STATEMENT

ASNC INFORMATION STATEMENT ASNC INFORMATION STATEMENT The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy Raymond R. Russell, MD, PhD, FASNC, a Jonathan

More information